EUVIMEDEUVIMED entdecken
Open Access

Androgen receptor in breast cancer and its clinical implication

Hannah Hackbart, Xiaojiang Cui, Jin Sun Lee

Translational Breast Cancer Research · 2023-10 · 4 · 30-30

DOI: 10.21037/tbcr-23-44 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2023-10. Verfasst von Hannah Hackbart und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is a heterogeneous group of diseases characterized by diverse subtypes. Currently, the classification of breast cancer is based on the status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). In addition to these receptors, the presence of the androgen receptor (AR) in breast cancer cells adds a layer of complexity to our understanding of the disease. The role of AR in breast cancer is intricate, as it can alter diverse signaling pathways in the presence of different hormone receptors (HRs). This complex interplay between signaling pathways affects patient outcomes and prognosis, and the presence of AR has a significant effect. While AR positivity is common in breast cancer, the efficacy of utilizing AR blockade as a monotherapy has been limited, demonstrating only modest results. To address this challenge, substantial efforts have been directed toward comprehending the intricacies of AR's role and pathways in breast cancer development in the hope of understanding its utility as a biomarker or drug target. Multiple ongoing clinical trials are currently investigating combination treatments involving AR inhibitors and other agents to disrupt oncogenic signaling pathways and their crosstalk. Particularly in the context of triple-negative breast cancer (TNBC), where targeted therapeutic options are lacking, extensive research efforts have been dedicated to exploring the potential of AR-related interventions. This review aims to provide an overview of the various breast cancer subtypes with AR signaling mechanisms, and ongoing clinical trials that hold the potential to reshape future clinical approaches.

Schlagwörter

Stichwörter der Autor:innen

Androgen receptor (AR)breast cancertriple-negative breast cancer (TNBC)

Autor:innen und Institutionen

  • Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Department of Surgery, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Hackbart, H., Cui, X., & Lee, J. S. (2023). Androgen receptor in breast cancer and its clinical implication. Translational Breast Cancer Research, 4, 30-30. https://doi.org/10.21037/tbcr-23-44

Vancouver

Hackbart H, Cui X, Lee JS. Androgen receptor in breast cancer and its clinical implication. Translational Breast Cancer Research. 2023;4:30-30. doi:10.21037/tbcr-23-44

BibTeX
@article{Hackbart2023,
  author = {Hackbart, Hannah and Cui, Xiaojiang and Lee, Jin Sun},
  title = {Androgen receptor in breast cancer and its clinical implication},
  journal = {Translational Breast Cancer Research},
  year = {2023},
  volume = {4},
  pages = {30--30},
  doi = {10.21037/tbcr-23-44}
}
Kostenlos starten →